Literature DB >> 19385976

Prognostic implication of SYT-SSX fusion type and clinicopathological parameters for tumor-related death, recurrence, and metastasis in synovial sarcoma.

Yan Sun1, Baocun Sun, Jian Wang, Wenjuan Cai, Xiulan Zhao, Shiwu Zhang, Xishan Hao.   

Abstract

The present study aimed to describe the distribution and features of the SYT-SSX fusion gene in Chinese patients with synovial sarcoma (SS), and to analyze the prognostic value of SYT-SSX fusion type and clinicopathological parameters for tumor-related death, recurrence, and metastasis in SS. SYT-SSX1 and SYT-SSX2 fusion transcripts were tested by reverse transcription-polymerase chain reaction in 141 formalin-fixed, paraffin-embedded SS. The prognostic implication of SYT-SSX fusion type and clinicopathological parameters were analyzed by univariate and multivariate survival analyses. SYT-SSX1 and SYT-SSX2 were detected in 50 (34.5%) and 91 (64.5%) tumors, respectively. SYT-SSX1 (risk ratio [RR] = 2.032, P = 0.004), larger tumor size (RR = 1.859, P = 0.008), and aggressive Fédération Nationale des Centers de Lutte Contre le Cancer grade (RR = 2.094, P = 0.001) were adverse predictors for disease-specific survival. However, SYT-SSX fusion type was not associated with local recurrence-free survival (P = 0.216). Patients with larger tumors (RR = 2.071, P = 0.005) and those who received marginal excision (RR = 2.556, P = 0.005) had poor local recurrence-free survival. Besides, SYT-SSX1 (RR = 1.859, P = 0.037), older age (RR = 1.799, P = 0.040), and aggressive International Union Against Cancer stage (RR = 3.690, P < 0.001) proved to be adverse prognostic factors for metastasis-free survival. In conclusion, compared to SYT-SSX1, SYT-SSX2 was more frequent in Chinese patients with SS. Moreover, SYT-SSX1 was an adverse predictor for disease-specific survival and metastasis-free survival, but had no relation to local recurrence-free survival. In addition, histological grade and tumor size were also important prognostic factors for SS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19385976     DOI: 10.1111/j.1349-7006.2009.01134.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  10 in total

1.  Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcoma.

Authors:  Bridget Charbonneau; Rachel Isaksson Vogel; J Carlos Manivel; Anthony Rizzardi; Stephen C Schmechel; Simona Ognjanovic; Subbaya Subramanian; David Largaespada; Brenda Weigel
Journal:  Hum Pathol       Date:  2013-05-10       Impact factor: 3.466

Review 2.  The SYT-SSX fusion protein and histological epithelial differentiation in synovial sarcoma: relationship with extracellular matrix remodeling.

Authors:  Tsuyoshi Saito
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

3.  Recurrent and novel SS18-SSX fusion transcripts in synovial sarcoma: description of three new cases.

Authors:  Joanna Przybyl; Raf Sciot; Piotr Rutkowski; Janusz A Siedlecki; Vanessa Vanspauwen; Ignace Samson; Maria Debiec-Rychter
Journal:  Tumour Biol       Date:  2012-09-14

4.  The clinical implication of SS18-SSX fusion gene in synovial sarcoma.

Authors:  T Ren; Q Lu; W Guo; Z Lou; X Peng; G Jiao; Y Sun
Journal:  Br J Cancer       Date:  2013-09-10       Impact factor: 7.640

5.  Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy.

Authors:  Joanna Przybyl; Monika Jurkowska; Piotr Rutkowski; Maria Debiec-Rychter; Janusz A Siedlecki
Journal:  Sarcoma       Date:  2012-03-25

6.  Investigation of osteosarcoma genomics and its impact on targeted therapy: an international collaboration to conquer human osteosarcoma.

Authors:  Ji-Long Yang
Journal:  Chin J Cancer       Date:  2014-11-21

Review 7.  Metastatic biomarkers in synovial sarcoma.

Authors:  Rosalia de Necochea-Campion; Lee M Zuckerman; Hamid R Mirshahidi; Shahrzad Khosrowpour; Chien-Shing Chen; Saied Mirshahidi
Journal:  Biomark Res       Date:  2017-02-07

8.  Genomic complexity in pediatric synovial sarcomas (Synobio study): the European pediatric soft tissue sarcoma group (EpSSG) experience.

Authors:  Daniel Orbach; Véronique Mosseri; Daniel Pissaloux; Gaelle Pierron; Bernadette Brennan; Andrea Ferrari; Frederic Chibon; Gianni Bisogno; Gian Luca De Salvo; Camille Chakiba; Nadège Corradini; Véronique Minard-Colin; Anna Kelsey; Dominique Ranchère-Vince
Journal:  Cancer Med       Date:  2018-03-13       Impact factor: 4.452

9.  Prognostic value of SS18-SSX fusion type in synovial sarcoma; systematic review and meta-analysis.

Authors:  Tadahiko Kubo; Shoji Shimose; Jun Fujimori; Taisuke Furuta; Mitsuo Ochi
Journal:  Springerplus       Date:  2015-07-25

10.  The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis.

Authors:  K B Jones; J J Barrott; M Xie; M Haldar; H Jin; J-F Zhu; M J Monument; T L Mosbruger; E M Langer; R L Randall; R K Wilson; B R Cairns; L Ding; M R Capecchi
Journal:  Oncogene       Date:  2016-03-07       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.